Login to Your Account

Albireo preps phase III plans for rare pediatric liver disease drug

By Michael Fitzhugh
Staff Writer

Monday, April 24, 2017

AMSTERDAM – New data on Albireo Pharma Inc.'s A-4250, an ileal bile acid transport inhibitor, has shown its capacity to reduce high levels of serum bile acids, which are often associated with severe itching, or pruritus, and liver damage in children with the rare cholestatic liver disease PFIC.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription